Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: BD MAX MRSA; SIRS-Lab Sepsis Test

Premium

Becton Dickinson said this week that its BD MAX MRSA molecular test has received a CLIA moderate complexity rating.

Performed on the automated BD MAX system, the assay is designed to rapidly and accurately identify patients colonized with methicillin-resistant Staphylococcus aureus. A moderate complexity rating allows the BD MAX MRSA assay to be performed by a qualified laboratory technician.

Earlier this year, the BD MAX GBS assay for Group B Streptococcus received a moderate complexity rating.


Germany's SIRS-Lab said this week that it has completed recruitment for a 1,000-patient trial to evaluate its Vyoo pathogen-detection assay for patients with suspected sepsis.

The prospective, blinded multicenter study focused on ICU patients at 13 key medical centers across Germany, SIRS-Lab said.

The Vyoo molecular test combines highly multiplexed qPCR with microarray analysis to identify molecular signatures of a variety of pathogens implicated in sepsis. The assay also uses a proprietary sample prep method that concentrates pathogen DNA from complex samples such as whole blood.

SIRS-Lab commenced the trial in March (PCR Insider, 3/24/2012). At the time, the company said that results would be available this year. This week, however, the company said that it expects results from the trial in 2013.

SIRS-Lab obtained CE marking for the current Vyoo test in May 2012. The company said this week that it has continued to invest in further automating Vyoo, reducing hands-on time for laboratory technicians to 70 minutes per run with an overall test time of seven hours.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.